ResearchAndMarkets.com released a comprehensive report analyzing over 1,859 clinical-stage pharmaceutical and biotechnology partnership deals announced since 2020. The report provides detailed financial terms, deal structures, contract documents, and insights into negotiation dynamics for clinical-stage drug development collaborations, serving as a benchmarking resource for biopharma dealmakers.

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

Takeda Pharmaceutical's AI-developed drug zasocitinib demonstrated statistical superiority over Bristol-Myers Squibb's deucravacitinib in a Phase 3 head-to-head trial for plaque psoriasis treatment. Zasocitinib achieved over 35% complete skin clearance (PASI 100) at week 16, more than 2.5 times the response rate of the competitor drug. The company plans to submit a New Drug Application to the FDA this fiscal year, with peak annual sales potential of $3-6 billion.

Ascentage Pharma announced Phase Ib study results showing olverembatinib combined with blinatumomab demonstrated encouraging clinical activity in patients with relapsed/refractory Ph+ BCP-ALL or CML-LBP, with 91% achieving complete response and manageable safety profile. The company presented six studies across three key assets at the 2026 ASCO Annual Meeting, marking its ninth consecutive appearance.

Ascentage Pharma presented updated clinical data at ASCO 2026 showing olverembatinib achieved a 91.3% complete cytogenetic response rate and 60.9% major molecular response rate at cycle 24 in CML-CP patients as second-line therapy. The drug demonstrated a stable safety profile with no new safety signals, supporting its potential role in treating patients who failed first-line TKI therapy.

The global tacrolimus market is projected to grow from USD 7.3 billion in 2025 to USD 12.7 billion by 2035 at a CAGR of 5.6%, driven by rising organ transplant procedures and increasing autoimmune disease prevalence. Injectable formulations and hospital settings dominate the market, with North America accounting for 40.4% of the market share. Key players are investing in R&D for improved formulations and expanding into emerging markets.

A Massachusetts jury awarded $884.9 million in damages against Takeda Pharmaceutical in an antitrust case related to its constipation drug Amitiza. The verdict stems from allegations that a 2014 settlement agreement between Takeda, Sucampo Pharmaceuticals, and Par Pharmaceutical delayed generic competition. The damages will automatically triple under U.S. antitrust law once judgment is entered. Takeda plans to appeal, defending the settlement as compliant with pharmaceutical patent dispute regulations.

The global stem cell therapy market is projected to grow from USD 21.9 billion in 2025 to USD 58.5 billion by 2034, driven by technological advancements, favorable regulations, and rising demand for regenerative medicine treatments for chronic diseases. North America leads the market with 48.87% share, while Asia-Pacific emerges as a key growth engine with recent approvals of iPSC-based therapies in Japan.

The IgA Nephropathy (IgAN) market is projected to grow at 18.6% CAGR through 2036, driven by rising disease prevalence, improved diagnostics, and a robust pipeline of novel immunotherapies. The market was valued at $1.5 billion in 2025, with recent FDA approvals including VOYXACT and multiple late-stage candidates from major pharmaceutical companies expected to reshape disease management.

The polycythemia vera market is expected to expand significantly by 2036, growing at 8.9% CAGR from a 2025 valuation of approximately USD 2 billion. Nine major pharmaceutical companies are advancing next-generation therapies in various clinical development stages, with rusfertide from Protagonist Therapeutics and Takeda expected to be the first new entrant to market this year, potentially reshaping the treatment paradigm beyond current standard therapies like JAKAFI, BESREMi, and PEGASYS.

Over 100 pharmaceutical companies are competing to develop 120+ pipeline drugs for non-small cell lung cancer (NSCLC), with approximately 30+ drugs in late-stage development. The competitive landscape is driven by precision oncology advances, including next-generation targeted agents and immunotherapy combinations. Recent FDA approvals and designations highlight innovation in treating EGFR-mutated, ALK-positive, and other biomarker-selected NSCLC populations.

Over 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include positive Phase III results from Alumis and Takeda, and regulatory progress from multiple companies, indicating robust innovation in the psoriasis treatment landscape.